Advertisement

Topics

The METRIC trial of tremelimumab, five years on

10:57 EDT 10 Sep 2017 | ecancermedicalscience

Prof Schadendorf speaks with ecancer at ESMO 2017 about the METRIC trial in melanoma, which initially showed a survival benefit for trametinib. He reports that, with 5 years of safety and survival data now available, the initial benefits have not...

Original Article: The METRIC trial of tremelimumab, five years on

NEXT ARTICLE

More From BioPortfolio on "The METRIC trial of tremelimumab, five years on"

Quick Search
Advertisement
 

Relevant Topic

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...